Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.
Read more ...
Barcelona, February 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced that VCN-01 at a dose of 3.3x1012 vp/patient can be safely administered in combination with Durbalumab when administered 15 days apart. Accordingly, in an Investigator Meeting, it was decided that VCN-01 will be further investigated at a higher dose of 1x1013 vp/patient in combination with Durvalumab.
Read more ...
Barcelona, November 27, 2020 – A team of researchers from SJD BarcelonaA team of researchers from SJD BarcelonaChildren’s Hospital and the biotechnology company VCN Biosciences, a Grifols company,has developed a world-first treatment which has prevented a child, who hadalready lost an eye to retinal cancer, from losing the other eye and becomingcompletely blind. As a result, Félix, who travelled from Venezuela to Barcelonaspecifically for the treatment, is now disease-free and retains his visual acuity, allowinghim to walk and play just as before. The treatment, which was administered as part ofa clinical trial, consists in injecting a genetically modified virus into the tumour-affectedeye. This virus can select, attack and destroy cancer cells.
Read more ...
September 3, 2019 –VCN Biosciences, a clinical–stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtainedwith its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September –1 October2019.
Read more ...
May 6, 2019 – VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products today announced that Manel Cascallo, Chief Executive Officer, will present at the following upcoming investor conferences:
Read more ...
January, 2019 -A team of researchers from SJD Barcelona Children’s Hospital has developed a new experimental treatment for retinoblastoma or tumour of the retina, a disease that accounts for 11% of malignancies in children under one year old. The treatment consists of injecting a genetically modified virus into the eye affected by the tumour.
Read more ...
January, 2019 –VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products, is pleased toannounce that a Phase 1 trial investigating its product VCN-01in combination with Durvalumab (MEDI4736),Astra-Zeneca’s anti-PD-L1 therapy,has recently obtained regulatory approval.
Read more...
November, 2016 – VCN Biosciences, a clinical –stage company developing oncolytic immunoncology products, is pleased to announce that preliminary clinical data on the Fist-in-Man Phase 1 clinical trial of VCN-01 after a single intravenous injection, either alone or combined with nab-paclixatel/gemcitabine will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, one of the world foremost oncology conferences on the latest developments in targets and drugs for cancer.
Read more ...
Fabruary, 2016 -After evaluating the safety and tolerability of the systemic administration of VCN-01 in monotherapy in P-VCNA-001 Phase 1 trial, Part II of this study is designed to determine the safety and biological activity of combining VCN-01 and chemotherapy (gemcitabine and Abraxane®).
Read more ...
February, 2016 -A consortium led by VCN Biosciencesreceives funding for Cure4RBproject (RTC-2015-4319-1)by Ministerio de Economía y Competitividad (MINECO)from Spanish Government, programRETOS DE COLABORACIÓN -2015.
Read more ...